Amgen Inc. has announced promising results from their scientific research in the field of obesity treatment. The company's efforts include groundbreaking work with GLP-1 research and a novel approach involving GIPR antagonism, which was validated through human data collected by Amgen's subsidiary, deCODE genetics. This research, supported by data from hundreds of thousands of individuals across various countries, has led to the development of a lead molecule targeting obesity. Currently in pre-clinical and clinical stages, Amgen is preparing for a potential global launch to ensure rapid accessibility for patients worldwide. The initiative, led by biopharmaceutical executive Susan Sweeney, aims to explore multiple indications for the treatment, marking a significant advancement in Amgen's mission to address obesity on a global scale.